CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE [Yahoo! Finance]
vTv Therapeutics Inc. - Class A (VTVT)
Last vtv therapeutics inc. - class a earnings: 7/31 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vtvtherapeutics.com
Company Research
Source: Yahoo! Finance
therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Stephen Marcus , M.D., Chief Executive Officer, will participate in the BIO CEO & Investor Conference being held February 26-27, 2024 in New York City During the conference, Dr. Marcus will conduct one-on-one meetings with registered investors, showcasing the Company's business and clinical development strategy, recent corporate achievements, and anticipated milestones. Cantex is developing azeliragon, an oral inhibitor of the receptor for advanced glycation end products (known as RAGE). Cantex has ongoing Phase 2 clinical trials in top US and EU medical centers in glioblastoma, brain metastasis, metastatic pancreatic cancer, and breast cancer, and a Phase 3 randomized, placebo-controlled clinical trial in hospitalized patients with pneumonia. Details of the event are as follows: Event: BIO CEO & Investor Conference Date & Time: February 26-
Show less
Read more
Impact Snapshot
Event Time:
VTVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTVT alerts
High impacting vTv Therapeutics Inc. - Class A news events
Weekly update
A roundup of the hottest topics
VTVT
News
- CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT [Yahoo! Finance]Yahoo! Finance
- CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMITPR Newswire
- vTv Therapeutics Inc. (NASDAQ: VTVT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateGlobeNewswire
VTVT
Earnings
- 5/11/23 - Beat
VTVT
Sec Filings
- 4/25/24 - Form DEF
- 4/10/24 - Form S-3
- 3/26/24 - Form 8-K
- VTVT's page on the SEC website